Invest in 5,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. more
Time Frame | EXAS | Sector | S&P500 |
---|---|---|---|
1-Week Return | -7.39% | 1.76% | 1.21% |
1-Month Return | -7.79% | -3.02% | -2.81% |
3-Month Return | -8.51% | 2.09% | 3.9% |
6-Month Return | -4.89% | 12.25% | 21.95% |
1-Year Return | -7.49% | 7.16% | 26.39% |
3-Year Return | -57.79% | 19.75% | 26.72% |
5-Year Return | -38.37% | 74.24% | 88.05% |
10-Year Return | 365.48% | 188.4% | 226.82% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 876.29M | 1.49B | 1.77B | 2.08B | 2.50B | [{"date":"2019-12-31","value":35.06,"profit":true},{"date":"2020-12-31","value":59.66,"profit":true},{"date":"2021-12-31","value":70.69,"profit":true},{"date":"2022-12-31","value":83.38,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 216.72M | 354.32M | 458.76M | 574.39M | 654.20M | [{"date":"2019-12-31","value":33.13,"profit":true},{"date":"2020-12-31","value":54.16,"profit":true},{"date":"2021-12-31","value":70.12,"profit":true},{"date":"2022-12-31","value":87.8,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 659.58M | 1.14B | 1.31B | 1.51B | 1.85B | [{"date":"2019-12-31","value":35.74,"profit":true},{"date":"2020-12-31","value":61.61,"profit":true},{"date":"2021-12-31","value":70.89,"profit":true},{"date":"2022-12-31","value":81.81,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 75.27% | 76.24% | 74.04% | 72.44% | 73.83% | [{"date":"2019-12-31","value":98.72,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":97.11,"profit":true},{"date":"2022-12-31","value":95.02,"profit":true},{"date":"2023-12-31","value":96.84,"profit":true}] |
Operating Expenses | 893.36M | 1.70B | 2.14B | 2.09B | 2.06B | [{"date":"2019-12-31","value":41.67,"profit":true},{"date":"2020-12-31","value":79.08,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":97.37,"profit":true},{"date":"2023-12-31","value":96.09,"profit":true}] |
Operating Income | (233.78M) | (558.35M) | (835.47M) | (577.54M) | (215.01M) | [{"date":"2019-12-31","value":-23378200000,"profit":false},{"date":"2020-12-31","value":-55835300000,"profit":false},{"date":"2021-12-31","value":-83546800000,"profit":false},{"date":"2022-12-31","value":-57754200000,"profit":false},{"date":"2023-12-31","value":-21501200000,"profit":false}] |
Total Non-Operating Income/Expense | (96.67M) | (386.78M) | (25.64M) | (74.66M) | 12.64M | [{"date":"2019-12-31","value":-764.48,"profit":false},{"date":"2020-12-31","value":-3058.77,"profit":false},{"date":"2021-12-31","value":-202.8,"profit":false},{"date":"2022-12-31","value":-590.45,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (268.85M) | (857.11M) | (842.51M) | (632.57M) | (201.75M) | [{"date":"2019-12-31","value":-26885100000,"profit":false},{"date":"2020-12-31","value":-85710500000,"profit":false},{"date":"2021-12-31","value":-84250600000,"profit":false},{"date":"2022-12-31","value":-63257000000,"profit":false},{"date":"2023-12-31","value":-20174600000,"profit":false}] |
Income Taxes | (184.86M) | (8.57M) | (246.88M) | (9.06M) | 2.40M | [{"date":"2019-12-31","value":-7692.8,"profit":false},{"date":"2020-12-31","value":-356.72,"profit":false},{"date":"2021-12-31","value":-10273.87,"profit":false},{"date":"2022-12-31","value":-377.2,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (83.99M) | (848.53M) | (595.63M) | (623.51M) | (204.15M) | [{"date":"2019-12-31","value":-8399300000,"profit":false},{"date":"2020-12-31","value":-84853300000,"profit":false},{"date":"2021-12-31","value":-59562500000,"profit":false},{"date":"2022-12-31","value":-62350600000,"profit":false},{"date":"2023-12-31","value":-20414900000,"profit":false}] |
Income From Continuous Operations | (83.99M) | (848.53M) | (595.63M) | (623.51M) | (204.15M) | [{"date":"2019-12-31","value":-8399300000,"profit":false},{"date":"2020-12-31","value":-84853300000,"profit":false},{"date":"2021-12-31","value":-59562500000,"profit":false},{"date":"2022-12-31","value":-62350600000,"profit":false},{"date":"2023-12-31","value":-20414900000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (83.99M) | (848.53M) | (595.63M) | (623.51M) | (204.15M) | [{"date":"2019-12-31","value":-8399300000,"profit":false},{"date":"2020-12-31","value":-84853300000,"profit":false},{"date":"2021-12-31","value":-59562500000,"profit":false},{"date":"2022-12-31","value":-62350600000,"profit":false},{"date":"2023-12-31","value":-20414900000,"profit":false}] |
EPS (Diluted) | (0.65) | (4.30) | (3.46) | (3.43) | (1.14) | [{"date":"2019-12-31","value":-65,"profit":false},{"date":"2020-12-31","value":-430,"profit":false},{"date":"2021-12-31","value":-346,"profit":false},{"date":"2022-12-31","value":-343,"profit":false},{"date":"2023-12-31","value":-113.57,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
EXAS | |
---|---|
Cash Ratio | 1.51 |
Current Ratio | 2.32 |
Quick Ratio | 2.07 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
EXAS | |
---|---|
ROA (LTM) | -3.04% |
ROE (LTM) | -6.60% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
EXAS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.51 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.49 |
Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. | 2.06 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
EXAS | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 5.18 |
P/B | 4.12 |
Price/FCF | 332 |
EV/R | 5.89 |
EV/Ebitda | 503.12 |
PEG | NM |
Exact Sciences Corp. (EXAS) just unveiled an update. Dr. Freda Lewis-Hall, a board member of Exact Sciences Corporation, plans to retire immediatel…
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P […]
MADISON, Wis. – Exact Sciences Corp. (NASDAQ:), known for its cancer screening and diagnostic tests, has announced the appointment of Aaron Bloomer as its new Chief Financial Officer, with his term set to begin on May 15, 2024. Bloomer will initially join the company as Executive Vice President of Finance and will transition into the […] The post Exact Sciences names Aaron Bloomer as new CFO By Investing.com appeared first on TheAdviserMagazine.com .
Exact Sciences Corp. (EXAS) has shared an update. Exact Sciences Corporation has announced the appointment of Aaron Bloomer as their new CFO, effec…
Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024. Mr. Bloomer brings to Exact Sciences more than 15 years of finance and accounting experience. He previously held leadership positions at Baxter International and 3M, where he helped improve financial Jetzt den vollständigen Artikel lesen
Exact Sciences appoints Aaron Bloomer as new Chief Financial Officer, bringing over 15 years of finance and accounting experience from companies like Baxter International and 3M. Bloomer''s global expertise in setting corporate strategy and driving growth will aid Exact Sciences in expanding its cancer screening and diagnostic tests portfolio.
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. In the first quarter, the fund’s Investor Class fund ARTMX returned 10.41%, Advisor Class fund APDMX posted a return of 10.40%, and Institutional Class fund APHMX returned 10.44%, compared […]
EXACT Sciences Corporation (EXAS) share price today is $58.79
Yes, Indians can buy shares of EXACT Sciences Corporation (EXAS) on Vested. To buy EXACT Sciences Corporation from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in EXAS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of EXACT Sciences Corporation (EXAS) via the Vested app. You can start investing in EXACT Sciences Corporation (EXAS) with a minimum investment of $1.
You can invest in shares of EXACT Sciences Corporation (EXAS) via Vested in three simple steps:
The 52-week high price of EXACT Sciences Corporation (EXAS) is $100.77. The 52-week low price of EXACT Sciences Corporation (EXAS) is $56.05.
The price-to-earnings (P/E) ratio of EXACT Sciences Corporation (EXAS) is NM
The price-to-book (P/B) ratio of EXACT Sciences Corporation (EXAS) is 4.12
The dividend yield of EXACT Sciences Corporation (EXAS) is 0.00%
The market capitalization of EXACT Sciences Corporation (EXAS) is $10.67B
The stock symbol (or ticker) of EXACT Sciences Corporation is EXAS